A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: November 8, 2007
Last updated: June 5, 2012
Last verified: June 2012
The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in combination with gemcitabine to patients with advanced pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer
Drug: CP-675,206 and gemcitabine
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Dose Limiting Toxicities: assessed through adverse event data collected weekly [ Time Frame: 8 week intervals ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • HAHA Response to CP-675,206: [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Lymphocyte Subset Analysis: [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Cytokine Analysis: [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Pharmacogenomic Analysis: [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Overall Survival: [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics of CP-675,206 and Gemcitabine: [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]
  • Best Overall Response: [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Duration of Tumor Response: [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Progression-Free Survival: [ Time Frame: 5 months ] [ Designated as safety issue: No ]

Enrollment: 37
Study Start Date: June 2008
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CP-675,206 and gemcitabine Drug: CP-675,206 and gemcitabine
Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with metastatic pancreatic cancer
  • Patient must have adequate bone marrow, liver and kidney function
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
  • Chemotherapy naive
  • Inoperable pancreatic cancer

Exclusion Criteria:

  • Patient must not have received prior systemic therapy for pancreatic cancer
  • Patient must not have previously received anti-CTLA4 therapy
  • History of chronic inflammatory or autoimmune disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00556023

Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
Research Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Research Site
Montreal, Quebec, Canada, H3T 1E2
Research Site
Candiolo (TO), Italy, 10060
Research Site
Roma, Italy, 00168
Sponsors and Collaborators
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00556023     History of Changes
Other Study ID Numbers: A3671016 
Study First Received: November 8, 2007
Last Updated: June 5, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016